Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma-Reference-Cited by-同舟云学术

Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma

Published:2019-08-19 Issue:4 Volume:84 Page:849-860
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kondo Eisei,Ikeda Takashi,Goto Hiroaki,Nishikori Momoko,Maeda Naoko,Matsumoto Kimikazu,Kitagawa Hideo,Noda Naoto,Sugimoto Saori,Hara Junichi

Funder

Dainippon Sumitomo Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03914-2.pdf

Reference48 articles.

1. Shay H, Sun DC (1955) Clinical studies of triethylenethiophosphoramide in the treatment of inoperable cancer. Cancer 8(3):498–511

2. Zarafonetis CJ, Shay H, Sun DC (1955) Triethylenethiophosphoramide in the treatment of chronic leukemia. Cancer 8(3):512–522

3. Jacobson PA, Green K, Birnbaum A, Remmel RP (2002) Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 49(6):461–467. https://doi.org/10.1007/s00280-002-0453-3

4. Breau AP, Field L, Mitchell WM (1984) Thiono compounds. 4. In vitro mutagenic and antineoplastic activity of TEPA and thio-TEPA. Cell Biol Toxicol 1(1):21–30

5. Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Mohle R, Roth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 3(8):e388–e397. https://doi.org/10.1016/s2352-3026(16)30050-3

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the outcomes of patients with primary central nervous system lymphoma between the neurosurgery and hematology/oncology departments based on the relative dose intensity of methotrexate;Oncology Letters;2023-09-19

2. Personalized hematopoietic stem cell transplantation for inborn errors of immunity;Frontiers in Immunology;2023-04-05

3. Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis;International Journal of Hematology;2023-01-23

4. High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors;Bone Marrow Transplantation;2022-11-03

5. Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?;Frontiers in Pharmacology;2022-03-07